Glabellar Lines

6

Review clinical trials related to Glabellar Lines. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Study to Assess the Safety and Efficacy of Co-Reconstituted TrenibotulinumtoxinE and OnabotulinumtoxinA in Adult Participants With Moderate to Severe Upper Facial Lines

The objective of this Phase 2 study is to assess the safety and efficacy of single treatment of trenibotulinumtoxinE and onabotulibumtoxinA combination in adult participants with moderate to severe upper facial lines. The study has two parts; Part 1 evaluates treatment for glabellar lines.

Participants needed: 300
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: AbbVieUpdated: Oct 13, 2026Locations: 1
Eligibility criteria

For glabellar lines (GL) indication: participant must have moderate or severe GL... [+2]

For GL Indication: Severe GL at rest as assessed by the investigator using the A... [+3]

Status: Recruiting

To Evaluate HU-045 With Moderate to Severe Glabellar Lines

A Multicenter, Double-blind, Randomized, Parallel, Active-controlled, Phase II Clinical Trial to Evaluate the Efficacy and Safety of HU-045 and Xeomin® in Patients With Moderate to Severe Glabellar Lines

Participants needed: 390
Trial details
Phase: Phase 3Age: 19-65Biological sex: AllType: InterventionalSponsor: Huons BiopharmaUpdated: Oct 13, 2026Locations: 1
Eligibility criteria

Adults aged 19 to 65 years, inclusive, as of the date of written informed consen... [+3]

Subjects with a known history of allergy or hypersensitivity to the investigatio... [+21]

Status: Recruiting

A Study to Evaluate Sequential Administration of Injections of AGN-151586 Followed by BOTOX in Adult Participants for Treatment of Glabellar Lines

Facial lines that develop from repeated facial expression, such as glabellar lines (GL), are typically treated by selectively weakening specific muscles with small quantities of botulinum toxin. The purpose of this study is to assess how safe and effective sequential administration of AGN-151586 and OnabotulinumtoxinA (BOTOX) is in adult participants with moderate to severe GL. AGN-151586 is an investigational drug being developed for treatment of moderate to severe glabellar lines. Participants are placed into 1 of 2 groups called treatment arms. In both arms participants will receive both AGN-151586 and BOTOX. Approximately 120 adult participants with moderate to severe glabellar lines enrolled in the study in approximately 8 sites around the United States. Participants will receive injections of AGN-151586 on Day 1 in the glabellar complex. After meeting treatment criteria, participants in Cohort 1 will receive intramuscular injections of BOTOX on Day 14, and participants in Cohort 2 will receive intramuscular injections of BOTOX on Day 21. Participants will be followed for up to approximately 141 days.

Participants needed: 120
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: AbbVieUpdated: Sep 9, 2026Locations: 8
Eligibility criteria

Moderate or severe glabellar lines (GL) at maximum frown as assessed by both the... [+2]

Severe glabellar lines at rest as assessed by the investigator using the FWS [+2]

Status: Not yet recruiting

Study of DWP450 in Japanese Subjects With Glabellar Lines

Study to Evaluate the Efficacy and Safety of DWP450 in Japanese Subjects with Moderate to Severe Glabellar Lines

Participants needed: 120
Trial details
Phase: Phase 3Age: 18-64Biological sex: AllType: InterventionalSponsor: Daewoong Pharmaceutical Co. LTD.Updated: Aug 26, 2026
Eligibility criteria

Male or female participants aged 18 to 64 years at the time of informed consent... [+3]

Subjects who are judged by the investigator to have glabellar lines that are not... [+4]

Status: Recruiting

To Evaluate HU-045 in the Treatment of Glabellar Lines(Phase III)

A Multicenter, Double-blind, Randomized, Parallel, Active-controlled, Phase II Clinical Trial to Evaluate the Efficacy and Safety of HU-045 and Xeomin® in Patients With Moderate to Severe Glabellar Lines

Participants needed: 312
Trial details
Phase: Phase 3Age: 19-65Biological sex: AllType: InterventionalSponsor: Huons BiopharmaUpdated: Oct 3, 2024Locations: 1
Eligibility criteria

19 Years to 65 Years(Adult, Older Adult) [+2]

Subject who has history of any diseases following. (myasthenia gravis, Eaton-Lam... [+18]